Home   Drug Development   CRO Services   Newsroom   About ReceptoPharm   Contact
» Recent News
» Archives
» E-Alerts
Drug Development

ReceptoPharm is developing proprietary therapeutic protein products for the treatment of neurological, viral and and autoimmune disorders.

» Learn More
CRO Services

ReceptoPharm offers a full range of contract research services catering to small and start-up biotech companies.

» Learn More


Nutra Pharma Receives Patent for Novel Antiviral Treatment using Modified Cobra Venom
July 28, 2010

Nutra Pharma has been issued a patent by the U.S. Patent and Trademark Office for a method of treating and preventing infectious diseases, including colds, flu viruses, and bacterial and parasitic infections, using modified and detoxified cobra venom and neurotoxins.

Nutra Pharma Corporation, a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), Multiple Sclerosis (MS) and Pain, announced today that it has received approval from the United States Patent and Trademark Office (USPTO) for its patent describing a method of treating and preventing infectious diseases, including colds, flu viruses, and bacterial and parasitic infections, using modified and detoxified cobra venom and neurotoxins.

The patent (US 7,758,894), titled “Modified elapid venoms as stimulators of the immune reaction,” describes a method for treating and inhibiting infections by influenza viruses through the use of subcutaneous, intramuscular, or intravenous injections of therapeutically effective amounts of a detoxified and neurotropically active oxidized alpha cobratoxin or alpha-cobrotoxin protein. The patent continues by explaining clinical evidence supporting marked increases in the expression of genes associated with the production of gamma interferon through exposure to these detoxified proteins. Gamma interferon is considered a potent antiviral agent and regulator of the immune response.

“This patent represents an important addition to our intellectual property portfolio,” commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “As we continue our efforts developing antiviral therapies using proteins from cobra venom, this patent will provide important ongoing support and protection of our research and development projects,” he explained.

Recently, Nutra Pharma, through its drug discovery subsidiary, ReceptoPharm, introduced its novel antiviral therapy, PEPTERON, at the International AIDS Conference in Vienna, Austria. PEPTERON is based on the Company's leading drug candidate using modified cobratoxin, RPI-MN, and has been shown to inhibit the entry of several viruses that are known to cause severe neurological damage in such diseases as encephalitis and HIV.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. Announcing the approval of the patent 7,758,894 should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at  Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Recent News
November 05, 2010
Nutra Pharma Awarded Grant under the Qualifying Therapeutic Discovery Project Program
Signup to receive news and announcements from ReceptoPharm and Nutra Pharma:
First Name:
Last Name: